Quidel Corporation

Global PCR (qPCR, dPCR, Singleplex & Multiplex) Markets Report 2021-2025 with Updated Impacts of COVID-19 Diagnostics - ResearchAndMarkets.com

Friday, May 7, 2021 - 5:35pm

b"Quidel Expects SARS-CoV-2 Testing Demand to Continue 'Through 2022, and Beyond'\nIsrael's Nucleix Targeting US Market With Noninvasive Bladder, Lung Cancer Assays\n"

Key Points: 

b"Quidel Expects SARS-CoV-2 Testing Demand to Continue 'Through 2022, and Beyond'\nIsrael's Nucleix Targeting US Market With Noninvasive Bladder, Lung Cancer Assays\n"

Quidel Forms Retail Collaboration With Walgreens for Over-the-Counter Sale of QuickVue® At-Home OTC COVID-19 Tests

Thursday, May 6, 2021 - 1:30am

The shelf-stable packages, each containing two of the self-administered rapid antigen tests, can also be ordered online at Walgreens.com for store pick-up or same day delivery.\n\xe2\x80\x9cThis retail collaboration with Walgreens will expedite in-store availability and over-the-counter sales of our QuickVue At-Home OTC COVID-19 antigen tests to consumers nationwide,\xe2\x80\x9d said Douglas Bryant, president and CEO of Quidel Corporation.

Key Points: 
  • The shelf-stable packages, each containing two of the self-administered rapid antigen tests, can also be ordered online at Walgreens.com for store pick-up or same day delivery.\n\xe2\x80\x9cThis retail collaboration with Walgreens will expedite in-store availability and over-the-counter sales of our QuickVue At-Home OTC COVID-19 antigen tests to consumers nationwide,\xe2\x80\x9d said Douglas Bryant, president and CEO of Quidel Corporation.
  • The QuickVue\xc2\xae At-Home OTC COVID-19 Test has not been FDA cleared or approved.
  • For more information about Quidel, visit quidel.com .\nThis press release contains forward-looking statements within the meaning of the federal securities laws that involve material risks, assumptions and uncertainties.
  • You are cautioned not to place undue reliance on these forward-looking statements, which reflect management\xe2\x80\x99s analysis only as of the date of this press release.

Quidel to Present Virtually at the BofA Securities 2021 Health Care Conference

Tuesday, May 4, 2021 - 11:00pm

b"Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the BofA Securities 2021 Health Care Conference, to be held virtually on Thursday, May 13, 2021.\nDouglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will present that day at 2:00 p.m. Eastern time (11:00 a.m. Pacific time) in a question-and-answer videoconference format.

Key Points: 
  • b"Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the BofA Securities 2021 Health Care Conference, to be held virtually on Thursday, May 13, 2021.\nDouglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will present that day at 2:00 p.m. Eastern time (11:00 a.m. Pacific time) in a question-and-answer videoconference format.
  • During the presentation, the company will discuss business and financial developments and trends.
  • An innovator for over 40 years in the medical device industry, Quidel pioneered the first FDA-cleared point-of-care test for influenza in 1999 and was the first to market a rapid SARS-CoV-2 antigen test in the U.S.
  • For more information about Quidel, visit quidel.com .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210504006325/en/\n"

2021 COVID-19 At-Home Testing Trends and Future Market Potential Report - ResearchAndMarkets.com

Tuesday, May 4, 2021 - 10:43am

b'Speculative Projection of Home Testing for Test Categories FY 2021 (COVID-19, UTIs, STDs, HIV, Cholesterol and Other Categories)\nNumber of Canada Authorized COVID-19 Testing Devices (Rapid Point-Of-Care, Antigen Testing Devices, Nucleic Acid Testing Devices [PCR], and Serological Testing Devices)\nSelected CE Marked Rapid, POC COVID-19 Tests (Abbott Laboratories, Cellex, Coris Bioconcept, Cue Health, HiberGene Diagnostics, Laipac Technology, LumiraDX, Mast Group, Mologic, MP Biomedicals, PerkinElmer, Roche Diagnostics, SD Biosensors, and Siemens Healthineers)\nMajor Sample Types Used in Rapid Diagnostic Tests For COVID-19 (Nasopharyngeal Swab, Anterior Nasal Swab, Saliva, and Breath)\nSelected COVID-19 Authorized Sample Collection Kits (Amazon, BioReference Laboratories, GenMark/Roche Diagnostics, Gravity Diagnostics, Laboratory Corp. America [LabCorp], LetsGetChecked, Quest Diagnostics, RapidRona, Walgreens, Color, DxTerity Diagnostics, Fluidigm, hims & hers, OraSure Technologies, Phosphorus Diagnostics, Thermo Fisher Scientific, Vitagene, and MicroGenDx)\nSelected COVID-19 Self-Tests Using A Nasal Swab (Abbott Labs, Becton Dickinson & Co [BD], Cue Health, Ellume, Eurofins Clinical Enterprise, Fulgent Genetics, Iowa State University, Laipac Technology, Lucira Health, Quidel Corp., Siemens Healthineers)\nSelected Saliva-Based Self-Tests for COVID-19 (Clinical Reference Laboratory, Fluidigm, Hoth Therapeutics, Medusa 19, Nuclein, OraSure Technologies, Vault Health, and Vitagene)\nSelected COVID-19 Tests Using Alternate Samples (Breathonix, Canary Health Technologies, Gadjah Mada University, GreyScan, Next-Gen, Northumbria University, Ohio State University, Scentech Medical, and PerkinElmer)\nMajor Test Technologies Used in Rapid Diagnostic Tests for COVID-19 (PCR, EIA, LF EIA, CRISPR, Biosensor, LAMP)\nSelected Home and POC Molecular COVID-19 Tests (Abbott Labs, BioFire Diagnostics/biomerieux,Cepheid, Clinical Reference Laboratory, Cue Health, Fluidigm, Fulgent Genetics, GenMark/Roche Diagnostics, HiberGene Diagnostics, Lucira Health, Mesa Biotech, OralDNA Labs, Vault Health, and Vitagene)\nSelected CRISPR and Biosensor-Based Devices for COVID-19 Testing (Arizona State University, Bilkent University, Blink Science, GLC Medical, Hoth Therapeutics, Identify Sensors Biologics, Iowa State University, Pennsylvania State University, Broad Institute of MIT, CSIR-Institute of Genomics, Gladstone Institutes, Mammoth Biosciences, and Sherlock Biosciences)\nSelected FDA EUA and CE Marked COVID-19 Antigen Immunoassays (Abbott Labs, AccessBio, Becton Dickinson & Co [BD] Ellume, Laipac Technology, Mast Group, Medusa 19, Mologic, PerkinElmer, Quidel Corp., Roche Diagnostics, SD Biosensor, and Siemens Healthineers)\nSelected FDA EUA and CE Marked COVID-19 Antibody Immunoassays (Assure Tech, bioLytical Laboratories, bio Merieux, Cellex, Eurofins Technologies, Healgen Scientific, NovaBay Pharmaceuticals, NOWDiagnostics, PerkinElmer, Quest Diagnostics, SD Biosensor, Vatic, and Verify Diagnostics)\nSelected OTC and DTC COVID-19 Test Initiatives (Abbott Labs, Becton Dickinson & Co [BD], Clinical Reference Laboratory, Cue Health, Ellume, Laboratory Corp. America [LabCorp], Laipac Technology, Lucira Health, Quest Diagnostics, and Quidel Corp.)\nSelected Novel COVID-19 Test Initiatives (3M, Fitbit, Identify Sensors Biologics, Johns Hopkins University, NeuTigers, Northwestern University, and Pennsylvania State University)\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210504005635/en/\n'

Key Points: 
  • b'Speculative Projection of Home Testing for Test Categories FY 2021 (COVID-19, UTIs, STDs, HIV, Cholesterol and Other Categories)\nNumber of Canada Authorized COVID-19 Testing Devices (Rapid Point-Of-Care, Antigen Testing Devices, Nucleic Acid Testing Devices [PCR], and Serological Testing Devices)\nSelected CE Marked Rapid, POC COVID-19 Tests (Abbott Laboratories, Cellex, Coris Bioconcept, Cue Health, HiberGene Diagnostics, Laipac Technology, LumiraDX, Mast Group, Mologic, MP Biomedicals, PerkinElmer, Roche Diagnostics, SD Biosensors, and Siemens Healthineers)\nMajor Sample Types Used in Rapid Diagnostic Tests For COVID-19 (Nasopharyngeal Swab, Anterior Nasal Swab, Saliva, and Breath)\nSelected COVID-19 Authorized Sample Collection Kits (Amazon, BioReference Laboratories, GenMark/Roche Diagnostics, Gravity Diagnostics, Laboratory Corp. America [LabCorp], LetsGetChecked, Quest Diagnostics, RapidRona, Walgreens, Color, DxTerity Diagnostics, Fluidigm, hims & hers, OraSure Technologies, Phosphorus Diagnostics, Thermo Fisher Scientific, Vitagene, and MicroGenDx)\nSelected COVID-19 Self-Tests Using A Nasal Swab (Abbott Labs, Becton Dickinson & Co [BD], Cue Health, Ellume, Eurofins Clinical Enterprise, Fulgent Genetics, Iowa State University, Laipac Technology, Lucira Health, Quidel Corp., Siemens Healthineers)\nSelected Saliva-Based Self-Tests for COVID-19 (Clinical Reference Laboratory, Fluidigm, Hoth Therapeutics, Medusa 19, Nuclein, OraSure Technologies, Vault Health, and Vitagene)\nSelected COVID-19 Tests Using Alternate Samples (Breathonix, Canary Health Technologies, Gadjah Mada University, GreyScan, Next-Gen, Northumbria University, Ohio State University, Scentech Medical, and PerkinElmer)\nMajor Test Technologies Used in Rapid Diagnostic Tests for COVID-19 (PCR, EIA, LF EIA, CRISPR, Biosensor, LAMP)\nSelected Home and POC Molecular COVID-19 Tests (Abbott Labs, BioFire Diagnostics/biomerieux,Cepheid, Clinical Reference Laboratory, Cue Health, Fluidigm, Fulgent Genetics, GenMark/Roche Diagnostics, HiberGene Diagnostics, Lucira Health, Mesa Biotech, OralDNA Labs, Vault Health, and Vitagene)\nSelected CRISPR and Biosensor-Based Devices for COVID-19 Testing (Arizona State University, Bilkent University, Blink Science, GLC Medical, Hoth Therapeutics, Identify Sensors Biologics, Iowa State University, Pennsylvania State University, Broad Institute of MIT, CSIR-Institute of Genomics, Gladstone Institutes, Mammoth Biosciences, and Sherlock Biosciences)\nSelected FDA EUA and CE Marked COVID-19 Antigen Immunoassays (Abbott Labs, AccessBio, Becton Dickinson & Co [BD] Ellume, Laipac Technology, Mast Group, Medusa 19, Mologic, PerkinElmer, Quidel Corp., Roche Diagnostics, SD Biosensor, and Siemens Healthineers)\nSelected FDA EUA and CE Marked COVID-19 Antibody Immunoassays (Assure Tech, bioLytical Laboratories, bio Merieux, Cellex, Eurofins Technologies, Healgen Scientific, NovaBay Pharmaceuticals, NOWDiagnostics, PerkinElmer, Quest Diagnostics, SD Biosensor, Vatic, and Verify Diagnostics)\nSelected OTC and DTC COVID-19 Test Initiatives (Abbott Labs, Becton Dickinson & Co [BD], Clinical Reference Laboratory, Cue Health, Ellume, Laboratory Corp. America [LabCorp], Laipac Technology, Lucira Health, Quest Diagnostics, and Quidel Corp.)\nSelected Novel COVID-19 Test Initiatives (3M, Fitbit, Identify Sensors Biologics, Johns Hopkins University, NeuTigers, Northwestern University, and Pennsylvania State University)\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210504005635/en/\n'

Quidel to Hold Fiscal First Quarter 2021 Financial Results Conference Call on May 6th, 2021

Tuesday, April 27, 2021 - 12:00am

During the conference call, the company will also discuss business and financial developments and trends.

Key Points: 
  • During the conference call, the company will also discuss business and financial developments and trends.
  • An innovator for over 40 years in the medical device industry, Quidel pioneered the first FDA-cleared point-of-care test for influenza in 1999 and was the first to market a rapid SARS-CoV-2 antigen test in the U.S.
  • With products made in America, Quidel\xe2\x80\x99s mission is to provide patients with immediate and frequent access to highly accurate, affordable testing for the good of our families, our communities and the world.
  • For more information about Quidel, visit quidel.com .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210426005928/en/\n"

Quidel Announces Preliminary Revenue for First Quarter 2021

Thursday, April 22, 2021 - 9:30pm

In the quarter, Quidel shipped nearly 15 million SARS tests, which compares favorably to the performance of our industry colleagues.

Key Points: 
  • In the quarter, Quidel shipped nearly 15 million SARS tests, which compares favorably to the performance of our industry colleagues.
  • COVID-19 revenues for the first quarter of 2021 are expected to be over $280 million, compared with $1.0 million for the first quarter of 2020.
  • The first quarter of 2021 was marked by the lack of a respiratory season, resulting in lower sales of influenza and other respiratory disease products.
  • Influenza revenues for the first quarter of 2021 are expected to be $5 million, compared with $79.6 million in the first quarter of 2020.

Quidel Corporation Partners With the Bay Area Lyme Foundation to Heighten Public Awareness of Lyme Disease

Tuesday, April 13, 2021 - 1:00pm

b"With Lyme disease season breaking out across the United States, Quidel Corporation announced today that it has partnered with the Bay Area Lyme (BAL) Foundation to help heighten public awareness to this alarming health condition that afflicts as many as 400,000 Americans each year.

Key Points: 
  • b"With Lyme disease season breaking out across the United States, Quidel Corporation announced today that it has partnered with the Bay Area Lyme (BAL) Foundation to help heighten public awareness to this alarming health condition that afflicts as many as 400,000 Americans each year.
  • Quidel is the nation\xe2\x80\x99s leading developer of rapid Lyme disease testing.\nAs part of its collaboration, Quidel will serve as the sponsor for BAL\xe2\x80\x99s series of free speaker forums that focus on research and science in the field of Lyme disease as well as Lyme disease prevention.
  • These events provide new information on various Lyme topics in an open-discussion format, all designed to bring awareness around the Lyme disease epidemic with rapid ways to diagnose and treat it.
  • \xe2\x80\x9cThat\xe2\x80\x99s why we are so honored to be partnering with the Bay Area Lyme Foundation.

Quidel Partners With San Diego Padres Organization for COVID-19 Testing

Friday, April 2, 2021 - 12:30am

Quidel Corporation (NASDAQ: QDEL) (Quidel), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that after several months supporting the Padres Front Offices efforts to reopen safely, Quidel has been chosen as Official Diagnostics Partner of the San Diego Padres Major League Baseball (MLB) franchise.

Key Points: 
  • Quidel Corporation (NASDAQ: QDEL) (Quidel), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that after several months supporting the Padres Front Offices efforts to reopen safely, Quidel has been chosen as Official Diagnostics Partner of the San Diego Padres Major League Baseball (MLB) franchise.
  • Quidels rapid antigen COVID-19 tests provide results in just 15 minutes, giving our Padres staff and Petco Park partners the confidence to feel Safe At Home at our ballpark.
  • San Diego is our home, and it gives our people tremendous pride to be the Official Diagnostics Partner of the Padres and to help ensure the entire Petco Park Team is Safe At Home.
  • Headquartered in San Diego, Quidel is a leading manufacturer of diagnostic solutions at the point of care, delivering a continuum of rapid testing technologies that further improve the quality of health care throughout the globe.

Quidel Corporation Applauds Biden Administration Plan to Expand COVID-19 Testing

Thursday, March 18, 2021 - 10:00pm

Quidel Corporation (NASDAQ: QDEL) (Quidel), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, today announced its support for the Biden Administrations plan to expand COVID-19 testing in schools, underserved communities, rural areas and other settings that have been gravely impacted by the pandemic.

Key Points: 
  • Quidel Corporation (NASDAQ: QDEL) (Quidel), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, today announced its support for the Biden Administrations plan to expand COVID-19 testing in schools, underserved communities, rural areas and other settings that have been gravely impacted by the pandemic.
  • Quidel applauds the Biden Administrations urgent and comprehensive approach to bringing the benefits of rapid, routine and equitable coronavirus testing to Americas classrooms, underserved communities and rural areas, said Douglas Bryant, president and CEO of Quidel Corporation.
  • Quidel is currently building out a new manufacturing facility in Carlsbad, CA dedicated to the production of Quidels popular QuickVue line of products.
  • Quidel Corporation (Nasdaq: QDEL) is a leading manufacturer of diagnostic solutions at the point of care, delivering a continuum of rapid testing technologies that further improve the quality of health care throughout the globe.

COVID-19 Market Will Reach 38 Billion by End of Year, Kalorama Finds

Thursday, February 25, 2021 - 11:05am

ARLINGTON, Va., Feb. 25, 2021 /PRNewswire/ --IVD market researcher Kalorama Information has published its first assessment of the COVID-19 market since last year.

Key Points: 
  • ARLINGTON, Va., Feb. 25, 2021 /PRNewswire/ --IVD market researcher Kalorama Information has published its first assessment of the COVID-19 market since last year.
  • The firm forecasts the market growing to $38 billion by year's end.
  • This is according to Kalorama's COVID-19 Testing Update 2021: Molecular & Antigen Markets, Procedures, Mutations, Home Tests, and Other Trends .
  • Becton Dickinson and Quidel are antigen players, longtime competitors in flu testing that have applied those systems to COVID-19 tests.